Previous 10 | Next 10 |
Epizyme’s Next EPIsode: Vision for Rewriting Oncology Treatment with Epigenetics Showcased New Five-Year Corporate Strategy Preliminary Safety and Activity Data from Ongoing Clinical Trials for TAZVERIK ® Combinations in Follicular Lymphoma and Prostate Cancer ...
Morgan Stanley has downgraded Epizyme ([[EPZM]] -1.8%) to equal-weight from overweight, The firm highlights the pandemic impact on Tazverik market launch with the price target cut to ~$14.00 from $27.00 per share implying ~37.4% upside to the previous close.The methyltransferase inhibitor pre...
The Next EPIsode: Epizyme’s Vision for Rewriting Oncology Treatment with Epigenetics Event to Showcase Epizyme’s Five-Year Corporate Strategy, TAZVERIK ® (tazemetostat) Ongoing Development Plans and Advancements in the Company’s Epigenetic Pipelin...
Image source: The Motley Fool. Epizyme Inc (NASDAQ: EPZM) Q4 2020 Earnings Call Feb 23, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Epizyme Inc (EPZM) Q4 2020 Earnings Call Transcript
Call Start: 08:00 Call End: 09:00 Epizyme, Inc. (EPZM) Q4 2020 Earnings Conference Call February 23, 2021, 8:00 am ET Company Participants Bill Slattery - IR, W2O Group Rob Bazemore - President & CEO Paolo Tombesi - CFO Vicki Vakiener - CCO Matt Ros - EVP, Chief Strategy and Business Offi...
Total Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020 TAZVERIK ® Net Revenues of $4.5 Million for 4Q 2020; $11.5 Million for FY 2020 Safety Run-In Portion of Confirmatory Trials of TAZVERIK® in ES and FL and Phase 1b Portion of Phase 1b/2 Cas...
Total Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020 TAZVERIK ® Net Revenues of $4.5 Million for 4Q 2020; $11.5 Million for FY 2020 Safety Run-In Portion of Confirmatory Trials of TAZVERIK ® in ES and FL and Phase 2 Castration-Resistan...
Epizyme (NASDAQ:EPZM) is scheduled to announce Q4 earnings results on Tuesday, February 23rd, before market open.The consensus EPS Estimate is -$0.59 (flat Y/Y) and the consensus Revenue Estimate is $6.55M (+52.7% Y/Y).Over the last 2 years, EPZM has beaten EPS estimates 88% of the time and h...
Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results a...
Today, we do a deep dive on Epizyme for the first time since March of last year. The stock is one of the few in the market near its 52-week lows. The name has become a 'battleground stock' among analysts as well. What is ahead for Epizyme in 2021? We try to answer that...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...